Positive association between SRA1 rs801460 variant and proliferative type of benign breast disease with atypia in Ukrainian females
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.16852Keywords:
benign breast disease, single nucleotide variant, SRAAbstract
Summary. Aim: To investigate the association between SRA1 rs801460 and rs10463297 variants and proliferative type of benign breast disease with atypia development in Ukrainian females. Materials and Methods: 83 individuals diagnosed with proliferative type of benign breast disease with atypia and 115 without atypia were enrolled in the study. The rs801460 and rs10463297 variants genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism analysis. Hematoxylin and eosin, toluidine blue and van Gieson’s picrofuchsin methods were used for sections staining. Results: It was revealed that SRA1 rs801460-variant is associated with proliferative type of benign breast disease with atypia development both before and after adjustment for risk factors (age, body mass index, age of menarche, oral contraceptives intake and burdened history of breast cancer). The risk for mentioned disease in the individuals with rs801460 TT-genotype is 2.2 times higher (confidence interval 1.010–4.800; p = 0.047) than in individuals with the CC and CT genotypes. No link between SRA1 rs10463297 and proliferative type of benign breast disease with atypia occurrence in Ukrainian females was found. Conclusion: The present study specified that SRA1 rs801460, but not rs10463297, can be the strong genetic predictor for benign breast disease with atypia in Ukrainian females.
References
World Health Organization. WHO Cancer Today, 2020. Retrieved from https://gco.iarc.fr/today/home
Shahpar S, Mhatre PV, Oza S. Rehabilitation. In: Bland KI, Copeland EM, Klimberg VS, et al., eds. The Breast (Fifth Edition). Elsevier, 2018: 1031–1038. https://doi.org/10.1016/B978-0-323-35955-9.00083-0
Breast Tumours. WHO Classification of Tumours, 5th Edition, Volume 2. WHO Classification of Tumours Editorial Board. IARC: Lyon 2019. 356 p.
Sasaki J, Geletzke A, Kass RB, et al. Etiology and Management of Benign Breast Disease. In: Bland KI, Copeland EM, Klimberg VS et al., eds. The Breast (Fifth Edition). Elsevier 2018: 79–92. https://doi.org/10.1016/B978-0-323-35955-9.00005-2
Calhoun BC, Grobmyer SR, Simpson JF. Benign, High-Risk, and Premalignant Lesions of the Breast. In: Bland KI, Copeland EM, Klimberg VS et al., eds. The Breast (Fifth Edition). Elsevier 2018: 116–29. https://doi.org/ 10.1016/B978-0-323-35955-9.00008-8
Vogel VG. Epidemiology of Breast Cancer. In: Bland KI, Copeland EM, Klimberg VS et al., eds. The Breast (Fifth Edition). Elsevier 2018: 207–18. https://doi.org/10.1016/ B978-0-323-35955-9.00015-5
Brisken C, O’Malley B. Hormone action in the mammary gland. Cold Spring Harb Perspect Biol 2010; 2: a003178. https://doi.org/10.1101/cshperspect.a003178
Lanz RB, McKenna NJ, Onate SA, et al. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 1999; 97: 17–27. https://doi.org/10.1016/S0092-8674(00)80711-4
Clarke RB. Human breast cell proliferation and its relationship to steroid receptor expression. Climacteric 2004; 7: 129–37. https://doi.org/10.1080/13697130410001713751
Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308–11. https://doi.org/10.1093/nar/29.1.308
Sheng L, Ye l, Zhang D, et al. New insights into the long non-coding RNA SRA: physiological functions and mechanisms of action. Front Med (Lausanne) 2018; 5: 244. https://doi.org/10.3389/fmed.2018.00244
Lanz RB, Chua SS, Barron N, et al. Steroid receptor RNA activator stimulates proliferation as well as apoptosis in vivo. Mol Cell Biol 2003; 23: 7163–76. https://doi.org/10.1128/ MCB.23.20.7163-7176.2003
Lukavenko IM, Kolnoguz AV, Kyrychenko MO, et al. Association between the rs801460-polymorphism in the SRA1 gene and thyroid nodules among Ukrainian women with proliferative type of benign breast dysplasia without atypia. East Ukr Med J. 2020; 8: 377–82. https://doi.org/10.21272/eumj.2020;8(4):377-382
Yan R, Wang K, Peng R, et al. Genetic variants in lncRNA SRA and risk of breast cancer. Oncotarget 2016; 7: 22486–96. https://doi.org/10.18632/oncotarget.7995
Leygue E. Steroid receptor RNA activator (SRA1): unusual bifaceted gene products with suspected relevance to breast cancer. Nucl Recept Signal 2007; 5: e006. https://doi.org/10.1621/nrs.05006
Deblois G, Giguere V. Ligand-independent coactivation of ERalpha AF-1 by steroid receptor RNA activator (SRA) via MAPK activation. J Steroid Biochem Mol Biol 2003; 85: 123–31. https://doi.org/10.1016/S0960-0760(03)00225-5
The 1000 Genomes Project Consortium. A global refe¬rence for human genetic variation. Nature 2015; 526: 68–74. https://doi.org/10.1038/nature15393
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
